Outcomes in COVID-19 selinexor studies

0 0.5 1 1.5+ All studies -286% 1 117 Improvement, Studies, Patients Relative Risk Mortality -286% 1 117 Ventilation -39% 1 117 ICU admission -11% 1 117 Viral clearance 21% 1 117 RCTs -286% 1 117 Late -286% 1 117 Selinexor for COVID-19 c19early.org November 2025 Favorsselinexor Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ XPORT-CoV-1001 Geils (SB RCT) -286% 3.86 [0.89-16.9] death 10/66 2/51 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.072 Late treatment -286% 3.86 [0.89-16.9] 10/66 2/51 286% higher risk All studies -286% 3.86 [0.89-16.9] 10/66 2/51 286% higher risk 1 selinexor COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.072 Effect extraction pre-specified(most serious outcome) Favors selinexor Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ XPORT-CoV-1001 Geils (SB RCT) -286% 3.86 [0.89-16.9] 10/66 2/51 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.072 Late treatment -286% 3.86 [0.89-16.9] 10/66 2/51 286% higher risk All studies -286% 3.86 [0.89-16.9] 10/66 2/51 286% higher risk 1 selinexor COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.072 Favors selinexor Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ XPORT-CoV-1001 Geils (SB RCT) -39% 1.39 [0.50-3.90] 9/66 5/51 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Late treatment -39% 1.39 [0.50-3.90] 9/66 5/51 39% higher risk All studies -39% 1.39 [0.50-3.90] 9/66 5/51 39% higher risk 1 selinexor COVID-19 mechanical ventilation result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Favors selinexor Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ XPORT-CoV-1001 Geils (SB RCT) -11% 1.11 [0.75-1.63] 33/66 23/51 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.61 Late treatment -11% 1.11 [0.75-1.63] 33/66 23/51 11% higher risk All studies -11% 1.11 [0.75-1.63] 33/66 23/51 11% higher risk 1 selinexor COVID-19 ICU result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.61 Favors selinexor Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ XPORT-CoV-1001 Geils (SB RCT) -16% 1.16 [0.62-2.18] no disch. 18/66 12/51 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.66 Late treatment -16% 1.16 [0.62-2.18] 18/66 12/51 16% higher risk All studies -16% 1.16 [0.62-2.18] 18/66 12/51 16% higher risk 1 selinexor COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.66 Favors selinexor Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ XPORT-CoV-1001 Geils (SB RCT) 21% 0.79 [0.62-1.01] viral+ 42/66 41/51 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.043 Late treatment 21% 0.79 [0.62-1.01] 42/66 41/51 21% lower risk All studies 21% 0.79 [0.62-1.01] 42/66 41/51 21% lower risk 1 selinexor COVID-19 viral clearance result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.043 Favors selinexor Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ XPORT-CoV-1001 Geils (SB RCT) -286% 3.86 [0.89-16.9] death 10/66 2/51 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.072 Late treatment -286% 3.86 [0.89-16.9] 10/66 2/51 286% higher risk All studies -286% 3.86 [0.89-16.9] 10/66 2/51 286% higher risk 1 selinexor COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.072 Effect extraction pre-specified(most serious outcome) Favors selinexor Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ XPORT-CoV-1001 Geils (SB RCT) -286% 3.86 [0.89-16.9] 10/66 2/51 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.072 Late treatment -286% 3.86 [0.89-16.9] 10/66 2/51 286% higher risk All studies -286% 3.86 [0.89-16.9] 10/66 2/51 286% higher risk 1 selinexor COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.072 Favors selinexor Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ XPORT-CoV-1001 Geils (SB RCT) -286% 3.86 [0.89-16.9] death 10/66 2/51 Improvement, RR [CI] Treatment Control XPORT-CoV-1001 Geils (SB RCT) -39% 1.39 [0.50-3.90] ventilation 9/66 5/51 XPORT-CoV-1001 Geils (SB RCT) -11% 1.11 [0.75-1.63] ICU 33/66 23/51 XPORT-CoV-1001 Geils (SB RCT) -16% 1.16 [0.62-2.18] no disch. 18/66 12/51 XPORT-CoV-1001 Geils (SB RCT) -4% 1.04 [0.70-1.55] no improv. 31/66 23/51 XPORT-CoV-1001 Geils (SB RCT) 21% 0.79 [0.62-1.01] viral+ 42/66 41/51 Selinexor COVID-19 outcomes c19early.org November 2025 Favors selinexor Favors control